Treatment for Cat-Scratch Disease with Fever and Lymphadenitis
Azithromycin is the recommended first-line treatment for cat-scratch disease presenting with fever and lymphadenitis, dosed at 500 mg on day 1 followed by 250 mg daily for 4 additional days (for patients >45 kg), or 10 mg/kg on day 1 then 5 mg/kg daily for 4 more days (for patients <45 kg). 1
Evidence-Based Rationale
The 2014 IDSA guidelines provide the strongest recommendation (strong, moderate quality evidence) for azithromycin based on the only placebo-controlled trial in cat-scratch disease. This study demonstrated that azithromycin-treated patients achieved 80% regression in lymph node size at 30 days significantly more often than placebo (P = 0.02). 1
Clinical Context
Cat-scratch disease, caused by Bartonella henselae, typically presents with:
- A papule or pustule developing 3-30 days after cat scratch or bite
- Regional lymphadenopathy appearing ~3 weeks after inoculation
- Lymph node suppuration in ~10% of cases
- Extranodal disease (CNS, liver, spleen, bone, lung) in ≤2% of cases
- Self-limited course with lymphadenopathy resolving within 1-6 months 1
Treatment Algorithm
For Immunocompetent Patients:
Standard therapy:
- Patients ≥45 kg: Azithromycin 500 mg PO day 1, then 250 mg PO daily × 4 days
- Patients <45 kg: Azithromycin 10 mg/kg PO day 1, then 5 mg/kg PO daily × 4 days 1
Alternative regimens (based on retrospective data, not controlled trials):
- Rifampin: 87% efficacy in retrospective series 2
- Ciprofloxacin: 84% efficacy in retrospective series 2, 3
- Trimethoprim-sulfamethoxazole: 58% efficacy 2
- Gentamicin IM: 73% efficacy 2
For Immunocompromised Patients (HIV/AIDS):
This is a different disease entity—bacillary angiomatosis:
- Erythromycin 500 mg QID for 2 weeks to 2 months, OR
- Doxycycline 100 mg BID for 2 weeks to 2 months 1
- May require >3 months of therapy 4
- Doxycycline ± rifampin for CNS involvement or severe disease 4
Important Clinical Caveats
Diagnostic Challenges:
- B. henselae is fastidious and rarely grows from cultures
- Serologic testing supports diagnosis but has cross-reactivity with B. quintana
- PCR is available but not standardized
- Warthin-Starry silver stain of lymph node tissue confirms diagnosis 1
Treatment Considerations:
Most cases do not require antibiotics: The majority of cat-scratch disease in immunocompetent hosts is self-limited and resolves without treatment. 5 However, treatment is indicated when:
- Fever is present (as in this case)
- Significant lymphadenopathy causes discomfort
- Systemic symptoms are prominent
- Extranodal involvement is suspected
Antibiotics with poor efficacy: Fourteen commonly used antibiotics showed little to no value in retrospective analysis, including penicillins and first-generation cephalosporins (which have no in vivo activity). 4, 2
Red Flags for Systemic Disease:
Patients with systemic involvement more frequently present with:
- Persistent fever (79.4% vs. 50.3% in localized disease) 6
- Elevated C-reactive protein (24.9 vs. 6.7 mg/L) 6
- Constitutional symptoms (weight loss, prolonged fever) 7, 6
These patients warrant evaluation for splenic/hepatic abscesses, chorioretinitis, osteomyelitis, or other extranodal disease and may require combination antibiotic therapy. 6
Special Populations:
Pregnant women: Azoles should be avoided; use local hyperthermia for cutaneous disease or amphotericin B for severe disease. 8
Children: Same azithromycin dosing as above (weight-based). 1
Bottom Line
While cat-scratch disease often resolves spontaneously, azithromycin is the evidence-based choice when treatment is warranted for fever and lymphadenitis, supported by the only randomized controlled trial and current IDSA guidelines. The 5-day course is well-tolerated, has proven efficacy in reducing lymph node size, and addresses the clinical symptoms that prompted treatment consideration.